Bal is an experienced patent attorney and has worked within the pharmaceutical field for over 20 years. He has a strong technical background and has held senior roles within both the R&D and IP functions of global pharmaceutical and drug delivery companies.
During his career he has built and defended patent portfolios protecting products at all stages of development, including a range of high-profile on-market medicines.
Bal has a first degree in Pharmacy and PhD in drug delivery and started his career with AstraZeneca as a senior product development scientist. During his time in this role, he led several technical programs to develop and repurpose drug candidates and is an inventor on patents protecting one of AZ’s oncology medicines.
In 2006, Bal transitioned into the IP department of AZ and progressed to the role of senior patent attorney. He has managed global patent portfolios protecting key products and he has also led IP due diligence activities for licensing and late-stage acquisitions. During his last 3 years at AZ, Bal was seconded into the litigation group to defend patents protecting a CNS product in multiple jurisdictions across Europe, South America and Asia.
Bal has developed an in-depth knowledge of the strategic aspects of multi-jurisdictional pharmaceutical patent litigation and also regularly acts as lead counsel in European patent opposition and appeal proceedings.
Since joining HGF, Bal has used his patent expertise and understanding of drug discovery and development to help clients focus their IP activities and achieve their commercial objectives.
Biopharmaceutics and Drug Delivery
Visiting lecturer at King’s College London and contribute to drug development modules of MPharm Pharmacy degree course.
Mentoring trainee patent attorneys.
Previously lectured on JDD course for EQE qualifications
The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’. Such a refusal can …Read article
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.